Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
Cornell's medical school and cancer centre in Manhattan, led by immunotherapy pioneer Jedd Wolchok, with major programmes in lymphoma, gastrointestinal and breast cancer.
Overview
The Sandra and Edward Meyer Cancer Center is the cancer centre of Weill Cornell Medicine, Cornell University's medical school on the Upper East Side of Manhattan, and delivers care with NewYork-Presbyterian Hospital. Jedd Wolchok, who led the CheckMate 067 and nivolumab-relatlimab melanoma trials, became its director in 2022. John Leonard's lymphoma programme led AUGMENT; Manish Shah's gastrointestinal oncology group led GLOW in claudin 18.2-positive gastric cancer; and Massimo Cristofanilli directs breast medical oncology and circulating tumour cell research.
- Immunotherapy
- Lymphoma
- Gastrointestinal oncology
- Breast oncology
Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive.
New York lymphoma specialist who led AUGMENT, the trial that established lenalidomide plus rituximab as a chemotherapy-free option for relapsed follicular and marginal zone lymphoma.
New York oncologist who was lead author of GLOW, one of the two trials that established zolbetuximab, the first drug aimed at claudin 18.2, for stomach cancer.
Showed that counting tumour cells in blood predicts survival in breast cancer and co-led PALOMA-3, which brought palbociclib to endocrine-resistant disease.
Similar pages
not linked directly; found by shared links- TrialAUGMENT
Shares John P. Leonard, Follicular lymphoma.
- PersonClifford A. Hudis
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.
- PersonPaul B. Chapman
- Key paperRibas and Wolchok 2018: cancer immunotherapy using checkpoint blockade
Shares Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center.
- PersonMonica Morrow
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.
- Key paperCheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later
Shares Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, Melanoma.
- PersonGilles Salles
Shares Follicular lymphoma, Memorial Sloan Kettering Cancer Center.
- PersonShanu Modi
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.